1. Indonesia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
PT Industri Jamu dan Farmasi Sido Muncul Tbk

PT Industri Jamu dan Farmasi Sido Muncul Tbk

IIDX:SIDO
350.00
IDR
+14.00
(+4.17%)
10.95TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
78.48
72.71
73.74
86.02
85.81
92.12
102.26
112.05
134.82
128.85
118.86
130.64
137.27
- -
Basic EPS, GAAP
13.43
13.81
14.54
16.14
17.8
22.13
26.93
31.38
42.28
36.82
31.69
39.03
41.36
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.97
13.4
11.96
12.37
12.9
21.83
21.34
26
34.14
36.2
35.6
36
42.9
22.04
Book Value per Share
86.46
86.84
87.17
91.97
96.55
96.77
102.17
107.4
115.72
116.85
112.86
116.26
106.01
101.75
Tangible Book Value per Share
86.46
83.82
84.1
88.92
93.16
92.1
97.63
103
111.39
112.54
108.59
111.96
101.57
97.32
Basic Weighted Avg Shares
30,229
30,229
30,088
29,781
29,993
29,995
29,996
29,768
29,826
30,000
30,000
30,000
29,720
29,385
Sales/Revenue/Turnover
2,372,364
2,197,907
2,218,536
2,561,806
2,573,840
2,763,292
3,067,434
3,335,411
4,020,980
3,865,523
3,565,930
3,919,084
4,079,659
- -
Operating Margin (%)
18.72
19.88
21.58
21.84
24.47
29.23
33.17
34.28
38.81
35.56
33.87
37.61
37.34
- -
Depreciation Expense
4,876
7,250
16,036
15,895
11,127
9,991
9,651
8,080
6,511
6,496
9,469
11,262
25,915
- -
Net Income, GAAP
405,943
417,510
437,474
480,525
533,799
663,849
807,689
934,016
1,260,898
1,104,714
950,648
1,171,026
1,229,202
- -
Effective Tax Rate (%)
30.33
23.91
21.94
23.61
21.72
23.51
24.78
22.14
21.84
22.2
22.05
22.46
21.93
- -
Profit Margin (%)
17.11
19
19.72
18.76
20.74
24.02
26.33
28
31.36
28.58
26.66
29.88
30.13
- -
Working Capital
2,042,163
1,679,007
1,523,379
1,578,439
1,420,394
1,175,217
1,307,365
1,492,038
1,701,337
1,653,194
1,604,791
1,792,235
1,472,073
1,391,479
LT Debt
- -
- -
- -
- -
- -
- -
- -
4,216
2,385
- -
3,300
- -
- -
- -
Total Equity
2,613,606
2,625,180
2,598,314
2,757,885
2,895,865
2,902,614
3,064,707
3,221,740
3,471,185
3,505,475
3,385,941
3,487,844
3,120,434
2,995,174
Return on Invested Capital (%)
13.78
12.35
14.26
16.38
17.57
21.35
25.06
27.25
34.8
29.44
25.83
32.17
35.03
- -
Return on Capital (%)
19.64
15.95
16.75
18.05
18.96
22.9
27.07
29.69
37.61
31.63
27.55
34.04
37.2
- -
Return on Common Equity (%)
20.72
15.94
16.75
17.94
18.88
22.9
27.07
29.72
37.68
31.67
27.59
34.07
37.2
- -

Capital Structure

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,110
1,591
1,591
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29,435
29,435
29,435
Market Capitalization
15,895,008
15,159,128
10,949,894

Working Capital

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,986,717
1,972,072
1,604,795
Cash, Cash Equivalents & STI
462,593
769,999
475,644
Accounts Receivable, Net
1,034,423
567,433
539,501
Inventories
466,149
572,820
554,099
Total Current Liabilities
514,644
336,123
213,316
Payables & Accruals
- -
- -
- -
ST Debt
4,110
1,591
1,591
Deferred Revenue
- -
- -
- -

Growth Rates

IDR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.99%
-0.44%
-10.53%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
11.94%
7.36%
4.97%
Sales/Revenue/Turnover
6.6%
4.59%
4.1%
Total Cash Common Dividend
15.1%
11.14%
18.06%

Quarterly Revenue

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,053,423
843,069
730,203
1,292,389
3,919,084
2025
789,105
1,039,600
- -
1,350,676
4,079,659
2026
640,499
826,159
- -
- -
- -

Quarterly Earnings Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13.02
7.27
5.65
13.1
39.03
2025
7.77
12.34
- -
13.95
41.36
2026
5.05
6.33
- -
- -
- -

Quarterly Dividends Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
18
36
2025
- -
- -
- -
22
42.9
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Irwan Hidayat
Full Time Employees
3,590
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Sido Muncul Ofc, Tentrem Hotel Bldg Semarang JT Indonesia 50134
IPO Date
Dec 18, 2013
Website
sidomuncul.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
PT Industri Jamu dan Farmasi Sido Muncul Tbk (SIDO.JK) manufactures and markets herbal medicines, supplements, food and beverages, and pharmaceuticals in Indonesia and select international markets. The company offers over 300 products across three main segments: herbal medicine and supplements including flagship Tolak Angin variants (Original, Anak, Flu, Batuk, Sugar Free), Tolak Linu, Esemag, Jamu Serbuk, soft capsules such as Vitamin D3 1000 IU, Vitamin E 300 IU, JSH Capsules, and herbal extracts/essential oils like patchouli oil via PT Semarang Herbal Indo Plant; food and beverages featuring Kuku Bima Ener-G! energy drinks in flavors like grape, orange, coffee, soda milk, and ready-to-drink formats, Susu Jahe ginger milk in Vanilla and Swiss Chocolate, ginger coffee, Vitamin C1000 in lemon and orange, and recent launches such as Natural Vitamin D3+K2, Natural Sari Daun Salam, Anak Sehat Susu in Grape & Strawberry, and Tentrem Teh Tarik; pharmaceuticals encompassing approximately 90 OTC and ethical products like Anacetine, Berlosid, Anabion, and Minyak Telon Cap Tiga Anak produced through subsidiary PT Berlico Mulia Farma. Founded in 1940 in Yogyakarta and established as a company in 1951, Sido Muncul maintains headquarters in Semarang, Central Java, with eight factories, one warehouse, and an extraction plant producing 12,500 kg daily; it operates a vast domestic distribution network via PT Muncul Mekar reaching over 188,000 outlets and 2.5 million points of sale from Sabang to Merauke, plus exports to 30 countries focused on Malaysia, Philippines, Nigeria via Muncul Nigeria Limited, and plans for expansion into Africa and Indochina. Recent developments include Affinity Equity Partners concluding its investment in April 2024 after supporting market leadership and operational enhancements, a share buyback program initiated in March 2025 repurchasing 217 million shares for IDR116 billion with IDR56 billion remaining through December 2025, four new product launches in 6M25, and a 17% YoY export sales increase contributing 9.7% to revenue amid 2024 net profit growth to IDR1.17 trillion.